Aegle Therapeutics Corp.

Aug 14, 2024

Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Trial of AGLE-102(TM) in Patients with Dystrophic Epidermolysis Bullosa ("DEB")

Oct 06, 2020

Aegle Therapeutics Receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for AGLE-102 for Patients with Dystrophic Epidermolysis Bullosa